TABLE 2.
Selected SNPs and the cumulative effect of unfavorable genotypes on recurrence in NMIBC patients receiving treatment of TUR alone
| SNP | Gene | Genotype | MOI* | Recurrence WW/WV/VV |
No recurrence WW/WV/VV |
HR (95 % CI)b | P | Q |
|---|---|---|---|---|---|---|---|---|
| rs3746162 | GPX4 | G/A | rec | 59/22/7 | 26/19/0 | 5.43 (2.19–13.46) | 0.0003 | 0.013 |
| rs451774 | GPX5 | A/G | rec | 41/36/11 | 21/24/0 | 2.45 (1.24–4.84) | 0.010 | 0.237 |
| rs1006771 | GSTT2 | T/G | rec | 38/38/12 | 17/26/2 | 2.24 (1.17–4.27) | 0.015 | 0.237 |
| rs2144698 | GSTA2 | G/T | dom | 53/26/9 | 16/19/10 | 0.61 (0.40–0.95) | 0.029 | 0.248 |
| rs367836 | GSTA4 | A/C | dom | 19/50/19 | 15/22/8 | 1.81 (1.06–3.08) | 0.029 | 0.248 |
| rs2180314 | GSTA2 | G/C | add | 44/32/12 | 14/15/16 | 0.72 (0.54–0.97) | 0.031 | 0.248 |
| rs17614751 | GSTA4 | G/A | dom | 80/8/0 | 35/10/0 | 0.45 (0.21–0.96) | 0.038 | 0.248 |
| Group (number of unfavorable genotypesa) | Recurrence | No recurrence | HR (95 % CI)b | P | MST (mo) |
|---|---|---|---|---|---|
| Low-risk group (0–2) | 30 | 29 | 1 (reference) | 21.7 | |
| Medium-risk group (3) | 7 | 24 | 2.44 (1.34–4.44) | 0.003 | 5.3 |
| High-risk group (4–6) | 8 | 38 | 2.53 (1.51–4.25) | 0.0004 | 5.9 |
| P trend | 0.0003 |
SNPs that continued to have a significant effect after correcting for multiple comparisons by Q value with a false discovery rate of ≤ 10 % are in boldface
rec recessive, dom dominant, add additive, WW homozygous wild-type genotype, WV heterozygous variant genotype, VV homozygous variant genotype, HR hazard ratio, CI confidence interval, MST median survival time, MOI model of inheritance
The model with the smallest P value
Unfavorable genotypes: GPX4 rs3746162 (vv); GPX5 rs451774 (vv); GSTT2 rs1006771 (vv); GSTA2 rs2144698 (ww); GSTA4 rs367836 (wv+vv); GSTA2 rs2180314 (vv); GSTA4 rs17614751 (ww)
Adjusted by age, sex, smoking status, cancer stage, and cancer grade